STUDY PROTOCOL

Obstetric and perinatal outcomes in female survivors of childhood or adolescent cancer: Protocol of a meta-analysis of population-based cohort studies

Fang Deng1,2‡, Xiuan Gao1‡, Limian Xu2, Weijie Li3, Zubing Mei4,5‡, Caijun Xie3‡*

1 Department of Gynecology of Traditional Chinese Medicine, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University (Foshan Maternity & Child Healthcare Hospital), Foshan, China, 2 Department of Gynecology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, 3 Department of Neurosurgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, 4 Anorectal Disease Institute of Shuguang Hospital, Shanghai, China, 5 Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

‡ FD, CX and XG contributed equally as co-first authors. CX and ZM contributed equally as co-corresponding authors.

* xiecaijun2008@126.com

Abstract

Introduction

Approximately 80% of children, adolescents and young adults (CAYA) cancer patients are expected to fully recover and survive for five years or more. The reproductive health is a particular area of their concern. Evidence demonstrates that previous therapeutic treatments for cancer and comorbidities may have harmful effects on female fertility and delivery outcomes, which will significantly affect patient quality of life. However, these reports are heterogeneous. Therefore, the purpose of this study is to provide the up-to-date evidence on the risk of adverse obstetric and perinatal outcomes in female survivors of childhood or adolescent cancer.

Methods and analysis

This meta-analysis will be carried out and reported with adherence to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and the Cochrane Handbook. We will search online databases including PubMed, Cochrane Library, and Embase from inception to August, 2022 to identify all relevant cohort studies examining the relationship between cancer and subsequent obstetric and perinatal outcomes. Data extraction from eligible studies will be conducted and crosschecked separately by two investigators using pre-tested standardized data extraction forms. Discrepancies will be resolved via a third investigator. Methodological quality assessment for each study will be conducted using the Newcastle–Ottawa scale (NOS) tool. We will apply the DerSimonian-Laird random-effects model to calculate the pooled estimates. Further sources of heterogeneity will be explored by performing subgroup analysis based on multiple study characteristics. Potential
Publication bias will be assessed by inspection of a funnel plot, Begg’s and Egger’s regression tests of funnel plot asymmetry.

**Ethics and dissemination**

Ethical approval will not be required as all data used for this pooled analysis will be obtained from published cohort studies. The results of this study will be disseminated in a peer-reviewed journal and conference presentation.

**OSF registration number**

DOI 10.17605/OSF.IO/K6QBG.

**Introduction**

The increase in the number of children, adolescents and young adults (CAYA) cancer patients is becoming a growing concern, and such patients are expected to fully recover and survive for a long time [1–3]. The overall five-year survival rate of CAYA cancer patients is reported to be approximately 80% [4, 5]. As these survivors reach childbearing age, they will face the risk of physical and psychosocial complications caused by cancer itself and its treatment and reproductive health is a particular area of their concern [6]. There is often concern that their previous diseases and treatments may have harmful effects on female fertility and delivery outcomes, which will significantly affect their quality of life [7, 8].

Previous studies have found that cancer survivors have a higher risk of preterm birth and postpartum hemorrhage than cancer-free women, and that these risks are further inflated in patients who receive pelvic or abdominal radiotherapy [9–14]. Kaidar-Person et al. found that breast cancer survivors had an increased risk of acute obstetrical complications during delivery compared to other compared to other mothers [15]. In a recent systematic review, cancer survivors were found to be at increased risk for undergoing selective and emergency caesarean sections, as well as assisted vaginal delivery and postpartum haemorrhage [16]. However, Zgardau and colleagues did not find a correlation between abdominal or pelvic radiation and preterm delivery [17], which contradicts the previous studies that radiation impairs the growth of the pelvis and uterus, resulting in limited uterine volume or impaired vascular supply to the fetus, leading to preterm delivery [18, 19]. They also found no increased risk of preeclampsia, caesarean section or gestational diabetes among cancer survivors, which diverged from previous studies [17].

These contradictory results prompt us to conduct a comprehensive and systematic review with meta-analysis on the risk of adverse obstetric and perinatal outcomes in female survivors of childhood or adolescent cancer based on published high-quality population-based cohort studies.

**Methods and analysis**

**Protocol registration**

This meta-analysis will be reported and conducted based on the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and the Cochrane Handbook (http://handbook.cochrane.org) [20]. Its protocol will be reported with adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines.
[21] (S1 Table). We have preregistered the protocol on the open science framework (OSF) website (https://osf.io/x2vra) with the registration number of DOI 10.17605/OSF.IO/K6QBG.

**Data sources and search strategies**

We will search online databases (i.e., PubMed, Cochrane Library, and Embase) from inception to August, 2022 using the specific search strategies as presented in Table 1, in order to identify all relevant cohort studies examining the relationship between cancer and subsequent obstetric and perinatal outcomes. Both Medical Subject Heading (MeSH) /EMBASE Subject Headings (Emtree) terms combined with free text words that are associated with cancer, obstetric outcomes, perinatal outcomes, and cohort study will be used. The keywords will be used to identify relative studies: one including terms on cancer (cancer*, tumor*, tumour*, oncolog*, neoplasm*, malignanc*, carcinoma*), the other one regarding obstetric or perinatal outcomes (obstetric outcomes, obstetric complications, perinatal outcomes, perinatal complications), which will be linked with the Boolean operators AND or OR. We will also check clinical trial registration, reference lists of included studies, conference proceedings and relevant reviews to identify additional eligible studies. Manual search of abstracts from annual meetings of the American Gynecological and Obstetrical Society (AGOS), European Society of Gynecology (ESGO), the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) will also be performed. When studies with duplicate data from the same cohort are published several times, only the most recent article with the largest population will be selected for inclusion. Search results will be imported into Endnote X7 (Thomson Reuters), where duplicate entries will be removed. Those additional duplicate entries will be manually removed by comparing authors, study titles and publication dates. Two authors will independently carry out the literature search, study selection, and the subsequent data extraction. Conflicts will be resolved by a senior author.

**Eligibility criteria**

Studies with all inclusion criteria satisfying the PECOS framework will be included in the qualitative and quantitative analyses.

- **Study question.** Are adverse obstetric and perinatal outcomes mostly due to cancer itself and cancer-related treatments for female survivors of childhood or adolescent cancer?

- **Study design.** Prospective or retrospective population-based cohort studies published in any languages will be considered eligible;

- **Populations.** This study will draw participants from female survivors of childhood or adolescent cancer diagnosed based on the International Classification of Diseases (ICD) criteria in the population-based cohort which reported one type of adverse obstetric and perinatal outcomes identified by ICD criteria;

- **Exposure.** The primary exposure of interest was defined as cancer diagnosis and cancer-related treatment including chemotherapy, radiotherapy, or other related antitumor therapies.

- **Comparators.** Studies will be included if they compared outcomes in the exposed group with those in a group of unexposed population (people who are cancer-free female controls).

- **Outcomes.** Studies will be included if one of the primary outcomes including any adverse obstetric outcomes, obstetric complications, perinatal outcomes and perinatal complications are reported and their risk estimates are provided.

**Data extraction**

Data extraction from eligible studies will be conducted and crosschecked separately by two investigators using pre-tested standardized data extraction forms. Discrepancies will be
Table 1. Search strategy for pubmed database.

**Cancer Survivor terms:**
1 "Cancer Survivors"[MeSH]
2 (cancer* or oncolog* or neoplasm* or carcinom* or tumor* or tumour* or malignan* or hematonoconological OR hemato oncological or hematonoconological or hematologic neoplasms or hematolo*)[Title/Abstract]
3 (survivor* OR surviving) [Title/Abstract]
4 and/2-3
5 1 or 4

**Obstetric/Perinatal Outcome terms:**
6 "Premature Birth"[Mesh]
7 (preterm or premature) [Title/Abstract]
8 "Infant, Low Birth Weight"[Mesh]
9 birth weight[Title/Abstract]
10 "Perinatal Death"[Mesh]
11 "Perinatal Mortality"[Mesh]
12 (perinatal mortality)[Title/Abstract]
13 "Intensive Care, Neonatal"[Mesh]
14 (neonatal and intensive care) [Title/Abstract]
15 "Fertility"[Mesh]
16 fertil* [Title/Abstract]
17 conception [Title/Abstract]
18 "Pregnancy"[Mesh]
19 pregnancy[Title/Abstract]
20 gestation*[Title/Abstract]
21 "Abortion, Spontaneous"[Mesh]
22 miscarriage* [Title/Abstract]
23 "Cesarean Section"[Mesh]
24 (cesarean or caesarean) [Title/Abstract]
25 "Obstetric Labor, Premature"[Mesh]
26 "Labor, Obstetric"[Mesh]
27 (labor or labour) [Title/Abstract]
28 "Fetal Membranes, Premature Rupture"[Mesh]
29 pPROM[Title/Abstract]
30 "Hypertension, Pregnancy-Induced"[Mesh]
31 "Pre-Eclampsia"[Mesh]
32 (Hypertens* and Pregnan*) [Title/Abstract]
33 (Preeclamp* or Pre-eclamp* or eclamp*)[Title/Abstract]
34 "Diabetes, Gestational"[Mesh]
35 (gestational diabetes) [Title/Abstract]
36 (pregnancy induced diabetes) [Title/Abstract]
37 (pregnancy-induced diabetes) [Title/Abstract]
38 GDM[Title/Abstract]
39 "Placenta Previa"[Mesh]
40 (Placenta abruption)[Title/Abstract]
41 "Premature Birth"[Mesh]
42 Preterm[Title/Abstract]
43 "Postpartum Hemorrhage"[Mesh]
44 (post-partum haemorrhage or postpartum haemorrhage or post-partum hemorrhage) [Title/Abstract]
45 ((neonatal or perinatal or fetal or birth* or deliver*) and outcome*)[Title/Abstract]

(Continued)
resolved via a third investigator. The following variables will be extracted from the included studies by applying a structured template: author of the publication, publication year, study set and design, research country and time range, participant mean or median age at cancer diagnosis, comparison population, criteria for ascertainment of cancer diagnosis and obstetric or perinatal outcomes, study results and risk estimates of the association of obstetric or perinatal outcomes with cancer.

Critical appraisal and methodological quality assessment
Methodological quality assessment for each study will be conducted using the Newcastle–Ottawa scale (NOS) tool for cohort studies, with focus on the major aspects including participant selection, comparability of study groups, and ascertainment of exposure and outcomes [22]. The full score is nine and the high-quality study is defined as a study with quality scores being more than 7 and moderate to low quality as no more than 7 [23].

Statistical analysis
We will carry out all statistical meta-analyses with the software Stata 15.0 (Stata Corp LP, College Station, TX). For each obstetric and perinatal outcome, the pooled relative risk (RR) in female cancer survivors compared with the RR in the cancer-free controls with its 95% CI will be estimated. To account for heterogeneity in the involved population, study setting or design,
and outcome assessment, we will apply the DerSimonian-Laird random-effects model to calculate the pooled estimates [24]. We will use the fully adjusted RRs for the association between cancer and the outcomes to derive pooled estimates and present the results with forest plots. Because the incidence of adverse obstetric or perinatal outcomes was low, the hazard ratio (HR) from cohort studies is approximated to RR and they can be combined for meta-analysis. We will evaluate the between-study heterogeneity by applying the chi-square test on Cochran’s Q statistic, which is quantified by the $I^2$ statistic, where an $I^2 > 50\%$ representing significant heterogeneity [25]. We will further explore sources of heterogeneity by performing subgroup analysis when two or more studies for each subgroup are available for a given outcome according to the following variables: study setting and design, research region, methodological quality, age, adjuvant therapy used, cancer site and follow-up period. Meta-regression will be performed for eligible investigated outcomes to further explore potential sources of heterogeneity. Potential publication bias will be assessed by inspection of a funnel plot and Begg’s and Egger’s regression tests of funnel plot asymmetry if 10 or more studies are involved in the meta-analysis [26, 27]. Sensitivity analysis will be performed by removing each study at a time and reanalyzing the others to assess whether any individual study will significantly affect the pooled estimates. If results indicate possible publication bias, adjusted risk estimates will be calculated using the Duval and Tweedie nonparametric trim-and-fill technique [28].

**Discussion**

To the best of our knowledge, this will be the first and most comprehensive meta-analysis to investigate the risk of adverse obstetric and perinatal outcomes in female survivors of childhood or adolescent cancer. This study will provide female cancer survivors with counseling and surveillance before and during pregnancy, and early risk warning for high-risk pregnant women who may develop adverse maternal outcomes, and offer evidence-based recommendations for those female survivors of childhood or adolescent cancer.

This study has several other strengths. Firstly, the Cochrane Handbook and PRISMA guideline will be strictly adhered to when conducting and reporting this meta-analysis and study quality of each included study will be assessed using NOS tool, which can objectively gain the quality of the pooled evidence. Secondly, by performing several subgroup analyses and sensitivity analyses, we can comprehensively explore the sources of between-study heterogeneity and confirm the robustness of the meta-analysis results. Finally, we will search the three major electronic databases and manually search other sources without language or date limitations to minimize the possibility of publication bias. Nevertheless, this study has a major limitation due to its anticipated significant between-study heterogeneity in that the included populations are female participants diagnosed with all types of cancer. However, this study is expected to reveal the relationship between cancer and obstetric and perinatal outcomes provide us a general risk estimate of obstetric and perinatal outcomes among female survivors of childhood or adolescent cancer.

**Supporting information**

S1 Table. PRISMA-P checklist. (DOC)

**Author Contributions**

**Conceptualization:** Fang Deng, Zubing Mei, Caijun Xie.

**Data curation:** Fang Deng, Limian Xu, Weijie Li, Caijun Xie.
Formal analysis: Caijun Xie.

Funding acquisition: Fang Deng, Limian Xu.

Investigation: Xiuan Gao, Weijie Li.

Methodology: Fang Deng, Limian Xu, Zubing Mei.

Project administration: Limian Xu.

Resources: Xiuan Gao, Limian Xu, Caijun Xie.

Supervision: Fang Deng.

Validation: Fang Deng, Xiuan Gao, Limian Xu, Weijie Li, Zubing Mei, Caijun Xie.

Visualization: Fang Deng, Limian Xu.

Writing – original draft: Fang Deng, Zubing Mei.

Writing – review & editing: Fang Deng, Zubing Mei, Caijun Xie.

References

1. Mulder RL, Font-Gonzalez A, Hudson MM, van Santen HM, Loeffen EAH, Burns KC, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology. 2021; 22(2):e45–e56. Epub 2021/02/05. https://doi.org/10.1016/S1470-2045(20)30594-5 PMID: 33539753.

2. Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, et al. Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors—presentation of the CARE for CAYA-Program study protocol and associated literature review. BMC cancer. 2020; 20(1):16. Epub 2020/01/08. https://doi.org/10.1186/s12885-019-6492-5 PMID: 31906955; PubMed Central PMCID: PMC6945396.

3. Howlader N, Noone A, Me Krapcho, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2016. National Cancer Institute. 2019;1.

4. Hilgendorf I, Bergelt C, Bokemeyer C, Kaatsch P, Seifart U, Stein A, et al. Long-Term Follow-Up of Children, Adolescents, and Young Adult Cancer Survivors. Oncology Research and Treatment. 2021; 44 (4):184–9. https://doi.org/10.1159/000514381 PMID: 33592618.

5. Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nature reviews Cancer. 2014; 14(1):61–70. Epub 2013/12/07. https://doi.org/10.1038/nrc3634 PMID: 24304873; PubMed Central PMCID: PMC6425479.

6. Dibble KE, Kaur M, Lyu J, Connor AE. Evaluation of health perceptions and healthcare utilization among population-based female cancer survivors and cancer-free women. Cancer causes & control: CCC. 2022; 33(1):49–62. Epub 2021/10/07. https://doi.org/10.1007/s10552-021-01498-y PMID: 34613541; PubMed Central PMCID: PMC8738151.

7. Griffiths MJ, Winship AL, Hutt KJ. Do cancer therapies damage the uterus and compromise fertility? Human reproduction update. 2020; 26(2):161–73. Epub 2019/12/22. https://doi.org/10.1093/humupd/dmz041 PMID: 31863097.

8. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. International journal of radiation oncology, biology, physics. 2009; 73(5):1304–12. Epub 2009/03/25. https://doi.org/10.1016/j.ijrobp.2008.12.016 PMID: 19306747; PubMed Central PMCID: PMC2865903.

9. van der Kooi ALF, Mulder RL, Hudson MM, Kremer LCM, Skinner R, Constine LS, et al. Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. American journal of obstetrics and gynecology. 2021; 224(1):3–15. Epub 2020/06/06. https://doi.org/10.1016/j.ajog.2020.05.058 PMID: 32502557.

10. Haggar FA, Pereira G, Preen D, Holman CD, Einarsson K. Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. PloS one. 2014; 9(12):e113292. Epub 2014/12/09. https://doi.org/10.1371/journal.pone.0113292 PMID: 25485774; PubMed Central PMCID: PMC4259305.
11. Lie Fong S, van den Heuvel-Eibrink MM, Eijkemans MJC, Schipper I, Hukkelhoven CWPM, Laven JSE. Pregnancy outcome in female childhood cancer survivors. Human Reproduction. 2010; 25(5):1206–12. https://doi.org/10.1093/humrep/deq029 PMID: 20172864
12. Sekiguchi M, Miyoshi Y, Kikuchi N, Sago H. Pregnancy outcomes in female childhood cancer survivors: Nationwide survey in Japan. Pediatrics International. 2018; 60(3):254–8. https://doi.org/10.1111.ped.13483 PMID: 29266574
13. van de Loo LEXM, van den Berg MH, Overbeek A, van Dijk M, Damen L, Lambalk CB, et al. Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors. Fertility and Sterility. 2019; 111(2):372–80. https://doi.org/10.1016/j.fertnstert.2018.10.016 PMID: 30691634
14. van Dijk M, van Leeuwen FE, Overbeek A, van Heuvel-Eibrink MM, van Dorp W, et al. Pregnancy, time to pregnancy and obstetric outcomes among female childhood cancer survivors: results of the DCOG LATER-VEVO study. Journal of Cancer Research and Clinical Oncology. 2020; 146(6):1451–62. https://doi.org/10.1007/s00432-020-03193-y PMID: 32221745
15. Kaidar-Person O, Yoel-Ullman R, Pillar N, Paluch-Shimon S, Poortmans P, Lawrence YR. Obstetric complications at time of delivery amongst breast cancer survivors: A population-based cohort study. Breast (Edinburgh, Scotland). 2022; 62:170–8. Epub 2022/02/27. https://doi.org/10.1016/j.breast.2022.02.008 PMID: 35219114
16. van der Kooi ALF, Kelsey TW, van den Heuvel-Eibrink MM, Laven JSE, Wallace WHB, Anderson RA. Perinatal complications in female survivors of cancer: a systematic review and meta-analysis. European journal of cancer (Oxford, England: 1990). 2019; 111:126–37. Epub 2019/03/09. https://doi.org/10.1016/j.ejca.2019.01.104 PMID: 30849686.
17. Zgardau A, Ray JG, Baxter NN, Nagamuthu C, Park AL, Gupta S, et al. Obstetric and Perinatal Outcomes in Female Survivors of Childhood and Adolescent Cancer: A Population-Based Cohort Study. Journal of the National Cancer Institute. 2022. Epub 2022/01/20. https://doi.org/10.1093/jnci/djac005 PMID: 35043954.
18. Teh WT, Stern C, Chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. BioMed research international. 2014; 2014:482968. Epub 2014/08/29. https://doi.org/10.1155/2014/482968 PMID: 25165706; PubMed Central PMCID: PMC4140124.
19. van der Kooi ALF, Brewster DH. Perinatal risks in female cancer survivors: A population-based analysis. 2018; 13(8):e0202805. https://doi.org/10.1371/journal.pone.0202805 PMID: 30138451.
20. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2019.
21. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015; 4(1): Epub 2015/01/03. https://doi.org/10.1186/s40647-014-0050-2 PMID: 25554246; PubMed Central PMCID: PMC4320440.
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in meta-analyses. European journal of epidemiology. 2010; 25(9):603–5. Epub 2010/07/24. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370.
23. Zhang F, Liu L, Zhang C, Ji S, Mei Z, Li T. Association of Metabolic Syndrome and Its Components With Risk of Stroke Recurrence and Mortality: A Meta-analysis. 2021; 97(7):e695–e705. https://doi.org/10.1212/wnl.0000000000012415 PMID: 34321360.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986; 7(3):177–88. Epub 1986/09/01. https://doi.org/10.1016/0197-2456(86)90046-2 PMID: 3802833.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003; 327(7414):557–60. Epub 2003/09/06. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120; PubMed Central PMCID: PMC192859.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997; 315(7109):629–34. Epub 1997/10/06. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563; PubMed Central PMCID: PMC2127453.
27. Beggb MB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088–101. Epub 1994/12/01. PMID: 7798990.
28. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455–63. Epub 2000/07/06. https://doi.org/10.1111/j.0006-341x.2000.00455.x PMID: 10877304.